Literature DB >> 14984498

Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia.

Derek L Stirewalt1, Soheil Meshinchi, Steven J Kussick, Kayla M Sheets, Era Pogosova-Agadjanyan, Cheryl L Willman, Jerald P Radich.   

Abstract

Internal tandem duplications in FLT3 are the most common mutation in acute myeloid leukaemia (AML), with agarose gel electrophoresis of polymerase chain reaction products (PCR/agarose) being the screening method of choice for these mutations. As PCR/agarose screening does not detect small mutations, single-stranded conformational polymorphism analyses (PCR/SSCP) were used in an attempt to identify previously unrecognized point mutations in FLT3 exons 14 and 15 of 140 AML patients, using newly designed primers that anneal within intron sequences. Novel missense point mutations were found in exon 14, suggesting additional investigations should be performed in AML and other haematopoietic malignancies, using this sensitive technique.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14984498     DOI: 10.1111/j.1365-2141.2004.04808.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

1.  Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.

Authors:  Derek L Stirewalt; Kenneth J Kopecky; Soheil Meshinchi; Julia H Engel; Era L Pogosova-Agadjanyan; Jeremy Linsley; Marilyn L Slovak; Cheryl L Willman; Jerald P Radich
Journal:  Blood       Date:  2005-12-20       Impact factor: 22.113

2.  FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.

Authors:  Hayley S Ma; Bao Nguyen; Amy S Duffield; Li Li; Allison Galanis; Allen B Williams; Patrick A Brown; Mark J Levis; Daniel J Leahy; Donald Small
Journal:  Cancer Res       Date:  2014-07-24       Impact factor: 12.701

3.  TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.

Authors:  Hayley Ma; Bao Nguyen; Li Li; Sarah Greenblatt; Allen Williams; Ming Zhao; Mark Levis; Michelle Rudek; Amy Duffield; Donald Small
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

Review 4.  Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

Authors:  Krzysztof Mrózek; Guido Marcucci; Peter Paschka; Susan P Whitman; Clara D Bloomfield
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

5.  Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis.

Authors:  David J Young; Bao Nguyen; Ruiqi Zhu; Jaesung Seo; Li Li; Mark J Levis; Keith W Pratz; Amy S Duffield; Donald Small
Journal:  Blood Adv       Date:  2021-05-11

6.  Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction.

Authors:  Carla S Wilson; George S Davidson; Shawn B Martin; Erik Andries; Jeffrey Potter; Richard Harvey; Kerem Ar; Yuexian Xu; Kenneth J Kopecky; Donna P Ankerst; Holly Gundacker; Marilyn L Slovak; Monica Mosquera-Caro; I-Ming Chen; Derek L Stirewalt; Maurice Murphy; Frederick A Schultz; Huining Kang; Xuefei Wang; Jerald P Radich; Frederick R Appelbaum; Susan R Atlas; John Godwin; Cheryl L Willman
Journal:  Blood       Date:  2006-04-04       Impact factor: 22.113

7.  High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.

Authors:  Marc M Loriaux; Ross L Levine; Jeffrey W Tyner; Stefan Fröhling; Claudia Scholl; Eric P Stoffregen; Gerlinde Wernig; Heidi Erickson; Christopher A Eide; Roland Berger; Olivier A Bernard; James D Griffin; Richard M Stone; Benjamin Lee; Matthew Meyerson; Michael C Heinrich; Michael W Deininger; D Gary Gilliland; Brian J Druker
Journal:  Blood       Date:  2008-02-05       Impact factor: 22.113

8.  ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.

Authors:  Deepa B Shankar; Junling Li; Paul Tapang; J Owen McCall; Lori J Pease; Yujia Dai; Ru-Qi Wei; Daniel H Albert; Jennifer J Bouska; Donald J Osterling; Jun Guo; Patrick A Marcotte; Eric F Johnson; Niru Soni; Kresna Hartandi; Michael R Michaelides; Steven K Davidsen; Saul J Priceman; Jenny C Chang; Katrin Rhodes; Neil Shah; Theodore B Moore; Kathleen M Sakamoto; Keith B Glaser
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

9.  Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.

Authors:  Hanna Janke; Friederike Pastore; Daniela Schumacher; Tobias Herold; Karl-Peter Hopfner; Stephanie Schneider; Wolfgang E Berdel; Thomas Büchner; Bernhard J Woermann; Marion Subklewe; Stefan K Bohlander; Wolfgang Hiddemann; Karsten Spiekermann; Harald Polzer
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

10.  FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.

Authors:  Benjamin H Lee; Zuzana Tothova; Ross L Levine; Kristina Anderson; Natalija Buza-Vidas; Dana E Cullen; Elizabeth P McDowell; Jennifer Adelsperger; Stefan Fröhling; Brian J P Huntly; Miloslav Beran; Sten Eirik Jacobsen; D Gary Gilliland
Journal:  Cancer Cell       Date:  2007-10       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.